bioRxivBioengineering
Formulation of a composite nasal spray enabling enhanced surface coverage and prophylaxis of SARS-COV-2
Abstract
Airborne pathogens pose high risks in terms of both contraction and transmission within the respiratory pathways, in particular the nasal region. Although knowledge of airborne transmission has long been known, there is little in the way of adequate intervention that can protect the individual, or even prevent further spread. This study focuses on a nasal applicant with the capacity to combat such issues, by focussing on the SARS-CoV-2 virus. Formulation of a spray containing polysaccharides known for their mucoadhesive properties was undertaken and characterised for their mechanical, spray patterns and antiviral properties. The ability to engineer key behaviours such as yielding have been shown, through systematic understanding of a composite mixture containing two polymers: gellan and {lambda}carrageenan. Furthermore, spray systems demonstrated highly potent antiviral capacities, resulting in complete inhibition of the virus when studied for both prophylaxis and prevention of spread. Finally, a mechanism has been proposed to explain such findings. Therefore, demonstrating the first fully preventative device, targeted to protect the lining of the upper respiratory pathways.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Iota carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture
J. C. Vega, S. Bansal, … C. Palacios·bioRxiv·Aug 19, 2020
- Mucin anchoring of SARS-CoV-2 neutralizing nanobinders increases intranasal antiviral efficacy
Joelton Rocha Gomes, Juliette Jacquelin, … Nicolas Meunier·bioRxiv·Apr 10, 2025
- SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray
K. Pyrc, A. Milewska, … I. F. Uchegbu·bioRxiv·Dec 10, 2020
- Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice
- Drug-free nasal spray as a barrier against SARS-CoV-2 infection: safety and efficacy in human nasal airway epithelia
F. Fais, R. Juskeviciene, … T. Meyer·bioRxiv·Jul 12, 2021
- A nasal vaccine candidate, based on S2 and N proteins from SARS-CoV-2, generates a broad antibody response systemic and at lower respiratory tract.
Yadira Lobaina, Rong Chen, … Lisset Hermida·bioRxiv·May 9, 2025